Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nuevos compuestos contra la tuberculosis

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20171019001
Publicado:
30/10/2017
Caducidad:
30/10/2018
Resumen:
Una universidad alemana ha desarrollado un antibiótico contra mycobacterium tuberculosis que no destruye los macrófagos, células que pertenecen al sistema inmune. Esta nueva clase de compuestos tiene el potencial de resolver los problemas de resistencia de mycobacterium tuberculosis a otros fármacos. Los compuestos también presentan una mayor bioactividad gracias a la permeabilidad optimizada a través de la pared celular de mycobacterium tuberculosis. La universidad busca compañías farmacéuticas con el fin de establecer acuerdos de licencia y cooperación en materia de investigación.

Details

Tittle:
Novel anti-tuberculosis compounds
Summary:
A German university developed an antibiotic that kills the mycobacterium tuberculosis without destroying the macrophages, cells that belong to the immune system. This novel class of compounds has the potential to overcome the resistance problems of mycobacterium tuberculosis to other drugs. The university is offering a license and research cooperation agreement.
Description:
The resurgence of tuberculosis, caused primarily by mycobacterium tuberculosis (Mtb), and the appearance of multi-drug and extensively drug resistant Mtb strains prove the need for new drugs with alternative modes of action. The interaction between the mycobacterial thioredoxin reductase (TrxR) and its substrate thioredoxin (Trx) is a promising new drug target for the treatment of tuberculosis, since Mtb lacks the common glutathione system and the mycobacterial TrxR shows a substantial difference in sequence, mechanism and structure to human TrxRs. It was shown that TrxR is essential for thiol redox homeostasis and genetic inactivation in vivo eradicates Mtb during acute and chronic mouse infections.

In order to further improve the bioactivity of promising compounds, researchers of a German university have focused on optimizing the physico-chemical properties that are important for permeability, since Mtb shows an unusual thick and impermeable cell wall.

The university offers a license and a research cooperation agreement to further develop the compounds and carry out tests. The profile addresses pharmaceutical companies.
Advantages and Innovations:
This offer introduces a novel class of compounds that inhibit a novel target with the potential to overcome resistance problems of mycobacterium tuberculosis to other drugs. In addition to that the viability of infected macrophages is not affected. The compounds also show an increased bioactivity by optimized permeability through the cell wall of mycobacterium tuberculosis
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A European patent has been filed.

Partner sought

Type and Role of Partner Sought:
The university offers a license and a research cooperation agreement. Possible research activities refer to the fact that the compounds have only been tested preclinical so far. In order to become a drug the compounds have to pass clinical studies and the approval process.
The profile addresses pharmaceutical companies that already have antibiotics in their portfolio.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002 Biología / biotecnología
06002001 Bioquímica / biofísica
06001 Medicina, salud humana
06001015 Productos farmacéuticos / medicamentos
06001018 Virus, virología / antibióticos / bacteriología